EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, Sara Lonardi iD, David Tougeron iD, Gianmarco Ricagno iD, Floriana Nappo iD, Ferdinando De Vita, Matthew Nankivell iD, David Cunningham iD, Jeeyun Lee iD, Won Ki Kang und 15 weitere

Journal of Clinical Oncology · 10.11.2025 · 43 (32) · 3457-3467

DOI: 10.1200/jco-25-00447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2025. Verfasst von Alessandra Raimondi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Microsatellite Instability, Esophageal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA) have better survival after surgery and scant/no benefit from chemotherapy. Preoperative immune checkpoint inhibitors (ICIs) demonstrated a high proportion of major complete pathologic response, possibly allowing chemotherapy/surgery-free approaches. METHODS Individual patient data pooled analysis was performed to determine an optimal strategy for resectable dMMR/MSI-H GEA. Patients were stratified across four groups: neoadjuvant dual CTLA-4/PD-(L)1 ICIs with or without surgery, perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) and surgery, and surgery alone or with older perioperative/adjuvant chemotherapy regimens. Primary end points were pathologic complete and major complete pathologic response proportion (pathologic complete response [pCR], tumor regression grade [TRG]1a, major pathologic response [MPR], TRG1a/b Becker criteria) in resected patients. Secondary end points were event-free survival (EFS) and overall survival (OS) in the overall population. RESULTS Among 197 patients, 49 received ICIs, 27 FLOT, 33 surgery alone, and 88 older chemotherapy regimens. Among 69 patients who underwent surgery after ICIs or FLOT, ICIs demonstrated significantly higher pathologic response versus FLOT (pCR, 61.9% v 3.7%; odds ratio [OR], 54.8; P = .002; MPR, 78.6% v 10%; OR, 39.3; P < .001) and lower ypN+ (14.3% v 37%; OR, 4.2; P = .015) and ypT (OR, 16.4; P < .001) stage. No significant differences in EFS/OS were observed (the 36-month EFS and OS were 70.4% v 80.6% and 72.7% v 90.4% with ICI v surgery alone). Residual nodal disease (ypN+) or ypT4 status after neoadjuvant ICIs or FLOT and nonpathologic response status were associated with inferior progression-free survival/OS. CONCLUSION In resectable dMMR/MSI-H GEA, neoadjuvant ICIs significantly increase pathologic response and downstaging versus FLOT, with comparable EFS/OS with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs versus FLOT should drive preoperative treatment choices in clinical high-risk disease. The high proportion of pCR/MPR with ICIs provides rationale for exploring organ-sparing surgery or nonoperative management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaMicrosatellite InstabilityEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsCTLA-4 AntigenB7-H1 AntigenHumansNeoadjuvant TherapyFemaleMaleMiddle AgedAgedDNA Mismatch RepairAdultChemotherapy, AdjuvantOxaliplatin

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenCTLA4 protein, humanB7-H1 AntigenCD274 protein, humanOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy.
  • Biostatistics for Clinical Research, Istituto Nazionale Tumori IRCCS, Milan, Italy.
  • Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.
  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

ORCID-Profile: Sara Lonardi, David Tougeron, Gianmarco Ricagno, Floriana Nappo, Matthew Nankivell, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Yoon Young Choi, Paolo Manca, Margherita Ambrosini, Roberta Fazio, Francesca Bergamo, Guillaume Piessen, Dominik Paul Modest, Rosalba Miceli, Thierry André, Filippo Pietrantonio

Zitieren

APA

Raimondi, A., Tinè, G., Ballhausen, A., Lonardi, S., Tougeron, D., Ricagno, G., Nappo, F., De Vita, F., Nankivell, M., Cunningham, D., Lee, J., Kang, W. K., Cheong, J. H., Choi, Y. Y., Randon, G., Prisciandaro, M., Pircher, C. C., Manca, P., Ambrosini, M., …, & Pietrantonio, F. (2025). Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. Journal of Clinical Oncology, 43(32), 3457-3467. https://doi.org/10.1200/jco-25-00447

Vancouver

Raimondi A, Tinè G, Ballhausen A, Lonardi S, Tougeron D, Ricagno G, et al. Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. Journal of Clinical Oncology. 2025;43(32):3457-3467. doi:10.1200/jco-25-00447

BibTeX
@article{Raimondi2025,
  author = {Raimondi, Alessandra and Tinè, Gabriele and Ballhausen, Alexej and Lonardi, Sara and Tougeron, David and Ricagno, Gianmarco and Nappo, Floriana and De Vita, Ferdinando and Nankivell, Matthew and Cunningham, David and Lee, Jeeyun and Kang, Won Ki and Cheong, Jae-Ho and Choi, Yoon Young and Randon, Giovanni and Prisciandaro, Michele and Pircher, Chiara C and Manca, Paolo and Ambrosini, Margherita and Fazio, Roberta and Bergamo, Francesca and Piessen, Guillaume and Smyth, Elizabeth C and Modest, Dominik Paul and Miceli, Rosalba and André, Thierry and Pietrantonio, Filippo},
  title = {Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {32},
  pages = {3457--3467},
  doi = {10.1200/jco-25-00447}
}
Kostenlos starten →